AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22959058 — intervention group
Group type: EXPERIMENTAL
Intervention: High-saturated-fatty-acid (HSFA) meal
Number of subjects: 39
Study 22959058 — intervention group
Group type: EXPERIMENTAL
Intervention: High-monounsaturated-fatty-acid (HMUFA) meal
Number of subjects: 39
Study 22959058 — intervention group
Group type: EXPERIMENTAL
Intervention: High-polyunsaturated-fatty-acid (HPUFA) meal with n-3 PUFA
Number of subjects: 39
Study 22959058 — intervention group
Group type: COMPARATOR
Intervention: High-polyunsaturated-fatty-acid (HPUFA) meal (placebo)
Number of subjects: 39
Study 20567511 — intervention group
Group type: EXPERIMENTAL
Intervention: Richly fortified porridge
Number of subjects: 743
Study 20567511 — intervention group
Group type: COMPARATOR
Intervention: Basal level porridge
Number of subjects: 743
Study 18226561 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm-cranking exercise
Number of subjects: 0
Study 18226561 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg-cranking exercise
Number of subjects: 0
Study 18226561 — intervention group
Group type: COMPARATOR
Intervention: Usual care controls
Number of subjects: 0
Study 17007343 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrofibre dressing (Aquacel)
Number of subjects: 61
Study 17007343 — intervention group
Group type: COMPARATOR
Intervention: Central pad dressing (Mepore)
Number of subjects: 61
Study 14730292 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraocular lens (IOL) implantation
Number of subjects: 30
Study 14730292 — intervention group
Group type: COMPARATOR
Intervention: Contact lens (CL) correction
Number of subjects: 30
Study 10399047 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping skills training
Number of subjects: 120
Study 10399047 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy according to Beck
Number of subjects: 120
Study 10399047 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy
Number of subjects: 120
Study 7554761 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc‐DTPA (intra-arterial injection)
Number of subjects: 16
Study 7554761 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc‐DTPA (intravenous injection)
Number of subjects: 16
Study 7554761 — intervention group
Group type: COMPARATOR
Intervention: 99mTc‐HSA (intra-arterial injection)
Number of subjects: 16
Study 2188543 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg of intravenous methylprednisolone
Number of subjects: 81
Study 2188543 — intervention group
Group type: COMPARATOR
Intervention: Intravenous normal saline (control)
Number of subjects: 81
Study 6110916 — intervention group
Group type: EXPERIMENTAL
Intervention: Imotest (disposable liquid tuberculin PPD)
Number of subjects: 0
Study 6110916 — intervention group
Group type: COMPARATOR
Intervention: Mantoux test
Number of subjects: 0
Study 6110916 — intervention group
Group type: EXPERIMENTAL
Intervention: Imotest
Number of subjects: 0
Study 31743812 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO) lipid emulsion, reduced to 0.4 g/kg daily
Number of subjects: 19
Study 31743812 — intervention group
Group type: COMPARATOR
Intervention: Olive/soybean (O/S) lipid emulsion, reduced to 0.4 g/kg daily
Number of subjects: 19
Study 30339669 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-week upper-extremity intervention
Number of subjects: 0
Study 30339669 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic characteristics and movement features
Number of subjects: 0
Study 30339669 — intervention group
Group type: EXPERIMENTAL
Intervention: LASSO model
Number of subjects: 0
Study 26679058 — intervention group
Group type: EXPERIMENTAL
Intervention: In-field gait retraining programme using mobile biofeedback, increasing step rate by 7.5% over preferred for 8 routine in-field runs.
Number of subjects: 30
Study 26679058 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified what intervention was provided).
Number of subjects: 30
Study 24886392 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention includes provision of kits with necessary medicines and laboratory supplies for ANC, a storage system, a tracking system, and training sessions for health care providers.
Number of subjects: 0
Study 24886392 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (first ANC visit)
Number of subjects: 0
Study 24886392 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (second and higher ANC visits)
Number of subjects: 0
Study 24886392 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 0
Study 23206490 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-operative intra-articular injection of magnesium sulphate and ropivacaine
Number of subjects: 80
Study 23206490 — intervention group
Group type: COMPARATOR
Intervention: Normal saline injection (control)
Number of subjects: 80
Study 20159292 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI (n=816)
Number of subjects: 1623
Study 20159292 — intervention group
Group type: COMPARATOR
Intervention: No MRI (n=807)
Number of subjects: 1623
Study 17630552 — intervention group
Group type: EXPERIMENTAL
Intervention: Genital HSV‐2 infection
Number of subjects: 441
Study 17630552 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervicovaginal HSV‐2 DNA
Number of subjects: 441
Study 17630552 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervicovaginal HIV‐1 RNA and HSV‐2 DNA correlation
Number of subjects: 441
Study 15810770 — intervention group
Group type: EXPERIMENTAL
Intervention: Single reminder trial
Number of subjects: 0
Study 11977510 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 29
Study 9643054 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual feedback
Number of subjects: 36
Study 9643054 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual + auditory feedback
Number of subjects: 36
Study 9643054 — intervention group
Group type: COMPARATOR
Intervention: Auditory feedback
Number of subjects: 36
Study 9643054 — intervention group
Group type: EXPERIMENTAL
Intervention: Distracting speech
Number of subjects: 36
Study 9643054 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood
Number of subjects: 36
Study 9643054 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased trait anxiety
Number of subjects: 36
Study 9643054 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectation
Number of subjects: 36
Study 9643054 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased anger-hostility, state-anxiety, and expectation
Number of subjects: 36
Study 8135721 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy alone
Number of subjects: 21
Study 8135721 — intervention group
Group type: COMPARATOR
Intervention: Desipramine alone
Number of subjects: 21
Study 8135721 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy combined with desipramine
Number of subjects: 21
Study 2674084 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous polyclonal 90‐Yttrium (90Y) labeled antiferritin, 10 mCi (1 patient), 20 mCi (4 patients), or 30 mCi (2 patients)
Number of subjects: 6
Study 2674084 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous polyclonal 90‐Yttrium (90Y) labeled antiferritin
Number of subjects: 6
Study 46959 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular injection of yttrium-90 (irradiation)
Number of subjects: 17
Study 46959 — intervention group
Group type: COMPARATOR
Intervention: Surgical synovectomy (control)
Number of subjects: 17
Study 30717707 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine with high-dose radiotherapy (arms C + D)
Number of subjects: 262
Study 30717707 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine with standard-dose radiotherapy (arms A + B)
Number of subjects: 262
Study 30717707 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine with high-dose radiotherapy and nelfinavir (arms A + C)
Number of subjects: 262
Study 30717707 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine with standard-dose radiotherapy and nelfinavir (arms B + D)
Number of subjects: 262
Study 30717707 — intervention group
Group type: EXPERIMENTAL
Intervention: Three more cycles of GEMABX (arm E)
Number of subjects: 262
Study 30717707 — intervention group
Group type: COMPARATOR
Intervention: All treatment arms
Number of subjects: 262
Study 28494751 — intervention group
Group type: EXPERIMENTAL
Intervention: Droxidopa
Number of subjects: 460
Study 28494751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 460
Study 25710876 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (0.5 mg) administered by inhalation 15 min before EVH
Number of subjects: 85
Study 25710876 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered by inhalation 15 min before EVH
Number of subjects: 85
Study 23011012 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 180
Study 23011012 — intervention group
Group type: COMPARATOR
Intervention: PCV7
Number of subjects: 180
Study 23011012 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 and PCV7
Number of subjects: 180
Study 21601418 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocular occlusion pupillometer
Number of subjects: 49
Study 21601418 — intervention group
Group type: COMPARATOR
Intervention: Free-viewing autorefractor pupillometer
Number of subjects: 49
Study 19370171 — intervention group
Group type: EXPERIMENTAL
Intervention: Plitidepsin 5mg/m2 (Arm A)
Number of subjects: 39
Study 19370171 — intervention group
Group type: EXPERIMENTAL
Intervention: Plitidepsin 7mg/m2 with L-carnitine (Arm B)
Number of subjects: 39
Study 19370171 — intervention group
Group type: COMPARATOR
Intervention: Both arms (Arm A and Arm B)
Number of subjects: 39
Study 19370171 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of L-carnitine
Number of subjects: 39
Study 16416227 — intervention group
Group type: EXPERIMENTAL
Intervention: High-caloric meal (3 kcal/min)
Number of subjects: 8
Study 16416227 — intervention group
Group type: COMPARATOR
Intervention: Low-caloric meal (1 kcal/min)
Number of subjects: 8
Study 15633483 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (RT) after adequate local excision (LE)
Number of subjects: 0
Study 15633483 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen
Number of subjects: 0
Study 11737438 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% diclofenac gel in 2.5% hyaluronan gel
Number of subjects: 96
Study 11737438 — intervention group
Group type: COMPARATOR
Intervention: Inactive gel vehicle (placebo)
Number of subjects: 96
Study 9067953 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cyclosporine
Number of subjects: 0
Study 9067953 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (high doses)
Number of subjects: 0
Study 9067953 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine in combination with corticosteroids
Number of subjects: 0
Study 9067953 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 7645572 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled bright light of 6,000‐12,000 lux on at least half of their 12‐hr night shifts for 3 months
Number of subjects: 13
Study 7645572 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambient light of 1,200‐1,500 lux
Number of subjects: 13
Study 7645572 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light technology
Number of subjects: 13
Study 2665389 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin/Gentamycin
Number of subjects: 354
Study 2665389 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotiam (Halospor)
Number of subjects: 354
Study 2665389 — intervention group
Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 354
Study 342619 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza virus vaccine (A/New Jersey/76 [Hsw1N1]) from four different manufacturers
Number of subjects: 0
Study 342619 — intervention group
Group type: EXPERIMENTAL
Intervention: Split‐product vaccine
Number of subjects: 0
Study 342619 — intervention group
Group type: EXPERIMENTAL
Intervention: Local reaction
Number of subjects: 0
Study 342619 — intervention group
Group type: EXPERIMENTAL
Intervention: All four vaccines
Number of subjects: 0
Study 342619 — intervention group
Group type: EXPERIMENTAL
Intervention: Split‐virus vaccine
Number of subjects: 0
Study 30880442 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplement containing a mixture of carotenoids, vitamins and omega-3 fatty acids (1 tablet/day)
Number of subjects: 80
Study 30880442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 31137872 — intervention group
Group type: EXPERIMENTAL
Intervention: Technical socks
Number of subjects: 109
Study 31137872 — intervention group
Group type: COMPARATOR
Intervention: Non-technical socks
Number of subjects: 109
Study 29262509 — intervention group
Group type: EXPERIMENTAL
Intervention: Weitan Waifu patch
Number of subjects: 120
Study 29262509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 25143719 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone-enanthate (125 mg/week)
Number of subjects: 60
Study 25143719 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (5 mg/day)
Number of subjects: 60
Study 25143719 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 60
Study 25143719 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for finasteride)
Number of subjects: 60
Study 22421906 — intervention group
Group type: EXPERIMENTAL
Intervention: 280 mg red wine polyphenols
Number of subjects: 61
Study 22421906 — intervention group
Group type: EXPERIMENTAL
Intervention: 560 mg red wine polyphenols
Number of subjects: 61
Study 22421906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 22421906 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses of polyphenol treatment
Number of subjects: 61
Study 20307804 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded tobacco‐use 'vital sign' intervention combined with fax referral to a quitline
Number of subjects: 1817
Study 20307804 — intervention group
Group type: COMPARATOR
Intervention: Traditional tobacco‐use vital sign alone
Number of subjects: 1817
Study 18353060 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 IU/kg vitamin D
Number of subjects: 37
Study 18353060 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 IU/kg vitamin D
Number of subjects: 37
Study 18353060 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 IU/kg vitamin D
Number of subjects: 37
Study 18353060 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 37
Study 15647405 — intervention group
Group type: EXPERIMENTAL
Intervention: EHCSS1
Number of subjects: 110
Study 15647405 — intervention group
Group type: EXPERIMENTAL
Intervention: EHCSS2
Number of subjects: 110
Study 15647405 — intervention group
Group type: COMPARATOR
Intervention: CC2
Number of subjects: 110
Study 15647405 — intervention group
Group type: COMPARATOR
Intervention: CC1
Number of subjects: 110
Study 15647405 — intervention group
Group type: COMPARATOR
Intervention: No smoking
Number of subjects: 110
Study 12639061 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Life in Epilepsy (QOLIE)-89
Number of subjects: 0
Study 10707140 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 0.5%
Number of subjects: 19
Study 10707140 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol 0.5%
Number of subjects: 19
Study 10707140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 7797777 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant tissue‐type plasminogen activator (rt‐PA)
Number of subjects: 395
Study 7797777 — intervention group
Group type: COMPARATOR
Intervention: primary coronary angioplasty
Number of subjects: 395
Study 2121359 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline (10 mg, once daily)
Number of subjects: 40
Study 2121359 — intervention group
Group type: COMPARATOR
Intervention: L-acetylcarnitine (500 mg, twice daily)
Number of subjects: 40
Study 219491 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-blocker
Number of subjects: 10294
Study 219491 — intervention group
Group type: EXPERIMENTAL
Intervention: diuretic
Number of subjects: 10294
Study 219491 — intervention group
Group type: EXPERIMENTAL
Intervention: central antihypertensive agent
Number of subjects: 10294
Study 30981150 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental pain induced by ultrasound‐guided injection of 1 mL hypertonic saline into the upper part of the right tibialis posterior muscle
Number of subjects: 12
Study 30981150 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline as non‐pain‐inducing control
Number of subjects: 12
Study 30981150 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental pain
Number of subjects: 12
Study 25854455 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% normal saline (non-balanced group)
Number of subjects: 30
Study 25854455 — intervention group
Group type: COMPARATOR
Intervention: Sterofundin®ISO (balanced group)
Number of subjects: 30
Study 26118476 — intervention group
Group type: EXPERIMENTAL
Intervention: VivaGel
Number of subjects: 0
Study 26118476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23569144 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg GTW daily, orally for 52 weeks
Number of subjects: 39
Study 23569144 — intervention group
Group type: COMPARATOR
Intervention: 4 g 5-ASA daily, orally for 52 weeks
Number of subjects: 39
Study 23569144 — intervention group
Group type: EXPERIMENTAL
Intervention: GTW
Number of subjects: 39
Study 23569144 — intervention group
Group type: COMPARATOR
Intervention: 5-ASA
Number of subjects: 39
Study 21332551 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin (500 mg every 12 h)
Number of subjects: 113
Study 21332551 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ceftriaxone (2.0 g per day for 7 days)
Number of subjects: 113
Study 21332551 — intervention group
Group type: EXPERIMENTAL
Intervention: Intestinal permeability index (IPI) measured the day after admission
Number of subjects: 113
Study 19857627 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy-density yogurt with inulin (6 g)
Number of subjects: 38
Study 19857627 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy-density yogurt (440 kcal; 0.9 kcal/g)
Number of subjects: 38
Study 19857627 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy-density yogurt (180 kcal; 0.4 kcal/g)
Number of subjects: 38
Study 19857627 — intervention group
Group type: COMPARATOR
Intervention: No beverage control condition
Number of subjects: 38
Study 19857627 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid orange juice (180 kcal)
Number of subjects: 38
Study 16707864 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% chloramine solution
Number of subjects: 40
Study 16707864 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% formalin solution
Number of subjects: 40
Study 16707864 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.02% thymol solution
Number of subjects: 40
Study 16707864 — intervention group
Group type: COMPARATOR
Intervention: ‐20 degrees C (no storage solution)
Number of subjects: 40
Study 15001599 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg daily)
Number of subjects: 0
Study 15001599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11139410 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 720
Study 11139410 — intervention group
Group type: COMPARATOR
Intervention: Social Behaviour and Network Therapy (SBNT)
Number of subjects: 720
Study 9232133 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil, 1 microgram/kg, given over 30 s followed by a continuous infusion of 0.1 microgram.kg‐1.min‐1
Number of subjects: 159
Study 9232133 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil+midazolam, 0.5 microgram/kg, given over 30 s followed by a continuous infusion of 0.05 microgram.kg‐1.min‐1
Number of subjects: 159
Study 9232133 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil+midazolam
Number of subjects: 159
Study 9232133 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 159
Study 8489539 — intervention group
Group type: COMPARATOR
Intervention: Auranofin (AUR)
Number of subjects: 281
Study 8489539 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 281
Study 3694018 — intervention group
Group type: EXPERIMENTAL
Intervention: Different follow-up groups with intervals of colorectal examination varying from 6 to 48 months after initial polypectomy
Number of subjects: 552
Study 3694018 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up programme
Number of subjects: 552
Study 3694018 — intervention group
Group type: COMPARATOR
Intervention: Colonoscopy
Number of subjects: 552
Study 29084479 — intervention group
Group type: COMPARATOR
Intervention: Classic laparoscopic dismembered pyeloplasty (Group I)
Number of subjects: 37
Study 29084479 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic in situ dismembered pyeloplasty (Group II)
Number of subjects: 37
Study 27721212 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 180 mg loading dose
Number of subjects: 76
Study 27721212 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 600 mg loading dose
Number of subjects: 76
Study 25509703 — intervention group
Group type: EXPERIMENTAL
Intervention: Spherical toric IOL, Acrys of SN60T (Group A)
Number of subjects: 44
Study 25509703 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspheric toric IOL, Acrts of SN6AT (Group B)
Number of subjects: 44
Study 22257673 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib plus trastuzumab
Number of subjects: 455
Study 22257673 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab
Number of subjects: 455
Study 22257673 — intervention group
Group type: COMPARATOR
Intervention: Lapatinib
Number of subjects: 455
Study 20332728 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercises program (COM) group
Number of subjects: 66
Study 20332728 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercises program plus jumping (COMpJ) group
Number of subjects: 66
Study 18248646 — intervention group
Group type: EXPERIMENTAL
Intervention: Staged diabetes management (SDM) strategy
Number of subjects: 193
Study 18248646 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 193